Form 4: Director Paul LaViolette Receives Edwards Lifesciences RSU

Director Paul A. LaViolette was granted 3,251 restricted stock units as part of the Edwards Lifesciences 2020 Nonemployee Directors Stock Incentive Program.

Summary

• Director Paul A. LaViolette acquired 3,251 restricted stock units (RSUs) on May 8, 2026.
• The grant was issued under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program.
• Following this transaction, the director's total direct beneficial ownership of common stock increased to 17,552 shares.
• The RSUs are scheduled to vest fully after one year or at the next annual meeting of stockholders, whichever occurs first.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no material impact on company operations or financial outlook.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The RSUs are set to vest in one year or upon the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that standard equity grants to non-employee directors are a common corporate governance practice to ensure long-term alignment with shareholder value in the medical device sector.

Comparison to Industry Standards

• The grant follows standard industry practices for non-employee director compensation packages among large-cap medical technology firms.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity incentive grant.

Next Steps

• Vesting of 3,251 restricted stock units in one year or at the next annual meeting.

Key Dates

Keywords

Edwards Lifesciences, EW, Form 4, Insider Trading, Director Compensation, Restricted Stock Units